Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Applied Biochemistry and Biotechnology|May 20, 2023
Expression, Purification, and Biological Evaluation of XTEN-GCSF in a Neutropenic Rat ModelFatemeh Yadavar Nikravesh, Parisa Gholami, Elham Bayat, et al.
Iranian Biomedical Journal|July 30, 2025
Development of Experimental Platforms to Assess Helicobacter pylori HopQ Interaction with Host CEACAM MoleculesNazanin Shans, Maryam Esmaeili, Kimia Abraheh, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|May 18, 2013
Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancerNajmeh Karami, Yeganeh Talebkhan, Samaneh Saberi, et al.
Scientific Reports|October 29, 2020
Improvement of Certolizumab Fab' properties by PASylation technologySomayeh Mazaheri, Yeganeh Talebkhan, Fereidoun Mahboudi, et al.
Preparative Biochemistry & Biotechnology|November 22, 2018
A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and E. coliFatemeh Naddafi, Farshad H Shirazi, Yeganeh Talebkhan, et al.
Current Pharmaceutical Design|March 14, 2024
Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor ActivityRada Dehghan, Arezoo Beig Parikhani, Reza Ahangari Cohan, et al.
AMB Express|February 10, 2024
A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeuticArezoo Beig Parikhani, Rada Dehghan, Yeganeh Talebkhan, et al.
Scientific Reports|January 14, 2022
Extension of human GCSF serum half-life by the fusion of albumin binding domainFatemeh Yadavar Nikravesh, Samira Shirkhani, Elham Bayat, et al.
Iranian Biomedical Journal|September 29, 2016
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric CancerYeganeh Talebkhan, Mohsen Doozbakhshan, Samaneh Saberi, et al.
Iranian Journal of Basic Medical Sciences|June 3, 2022
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidateAkbar Oghalaie, Fereidoun Mahboudi, Fatemeh Rahimi-Jamnani, et al.
Pageof 5